<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114333</url>
  </required_header>
  <id_info>
    <org_study_id>13-3192</org_study_id>
    <nct_id>NCT02114333</nct_id>
  </id_info>
  <brief_title>Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds</brief_title>
  <official_title>A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the two vaccines that have been developed to prevent and/or lessen&#xD;
      the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other,&#xD;
      herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an&#xD;
      ingredient that may enhance the body's immune response to the vaccine, and is currently&#xD;
      investigational. The vaccines are being compared to assess their ability to stimulated&#xD;
      protection against shingles. The study will provide an opportunity to determine the safety&#xD;
      profile of each vaccine in a single trial. The study will also look at the effect of age on&#xD;
      the immune response to the two vaccines and on the persistence of these responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      160 people from the Denver area will participate. Duration is up to 5 years with 10-12 visits&#xD;
      in that period. Subjects are randomized into one of 4 arms to receive either Zostavax or&#xD;
      HZ/su. In this single blind study all subjects receive 2 injections: one at the first visit&#xD;
      (Day 0) and the second at Day 60. HZ/su subjects will receive vaccine at both visits;&#xD;
      Zostavax subjects will receive vaccine at the first visit and a placebo at the Day 60 visit.&#xD;
      Blood is collected from all subjects at most visits. Some subjects spit into a tube for&#xD;
      saliva collection. A urine sample is collected prior to vaccination if subject is a woman of&#xD;
      childbearing potential. Subjects are asked to complete a diary to record any reactions in the&#xD;
      30 days after each injection. The Day 90 visit is the last one until the annual visits for&#xD;
      blood draws begin at Day 365. Some subjects are also seen at Year 2 and Year 4; all subjects&#xD;
      are seen at Year 5 for blood draw.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Interferon gamma/ Interleukin 2 (IFNg/IL2) dual color fluorospot number</measure>
    <time_frame>Measured up to Day 730</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glycoprotein-based enzyme-linked immunosorbent assay (gpELISA)</measure>
    <time_frame>Measured up to Day 730</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Unsolicited adverse events</measure>
    <time_frame>Within 30 days of each vaccination</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Shingles</condition>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No previous zoster vaccine; stratified between age groups 50-59 and 70-85&#xD;
First dose live vaccine, Zostavax (0.65ml, subcutaneous)&#xD;
Second dose placebo, normal saline (0.65ml. subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - recombinant zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No previous zoster vaccine; stratified between age groups 50-59 and 70-85&#xD;
First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)&#xD;
Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One previous dose of zoster vaccine at least 5 years previously, age 70-85&#xD;
First dose live vaccine, Zostavax (0.65ml, subcutaneous)&#xD;
Second dose placebo, normal saline (0.65ml. subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - recombinant zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One previous dose of zoster vaccine at least 5 years previously, age 70-85&#xD;
First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)&#xD;
Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>0.65ml, subcutaneous</description>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HZ/su vaccine</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>B - recombinant zoster vaccine</arm_group_label>
    <arm_group_label>D - recombinant zoster vaccine</arm_group_label>
    <other_name>Recombinant vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.65ml, subcutaneous</description>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of varicella or residence int he US for 30 years&#xD;
&#xD;
          -  For Arms C and D - prior live zoster vaccine at least 5 years previously&#xD;
&#xD;
          -  For Arms A and B - Age 50-59 or 70-85&#xD;
&#xD;
          -  For Arms C and D - Age 70-85&#xD;
&#xD;
          -  For women of childbearing potential, a negative pregnancy test and agreement to use&#xD;
             adequate contraception from 30 days before until 3 months after the last dose of any&#xD;
             study vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of herpes zoster&#xD;
&#xD;
          -  For Arms A and B - prior live zoster vaccine&#xD;
&#xD;
          -  Immune compromising illness or therapies or chronic illness&#xD;
&#xD;
          -  Allergy to previous herpes zoster vaccine&#xD;
&#xD;
          -  Other investigational drugs or vaccines within the past 6 months before the study and&#xD;
             until last visit&#xD;
&#xD;
          -  Blood products for 3 months prior to or planned during the study&#xD;
&#xD;
          -  Concomitant non-topical antiviral therapy within 3 days prior to and 7 days after&#xD;
             vaccination.&#xD;
&#xD;
          -  Vaccines within 2 weeks (inactive vaccine) or 4 weeks (live vaccine) prior to the&#xD;
             study until 30 days after any dose of either vaccine.&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Current drug addiction or alcoholism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron J Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shingles vaccine</keyword>
  <keyword>Immune response</keyword>
  <keyword>Zoster vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

